 Chemotherapy-induced cognitive impairment CICI, also known as chemobrain, is a spectrum of neurocognitive deficits experienced during and after the administration of chemotherapy for cancer. The incidence of CICI is significant, affecting anywhere from 25 to 75 of survivors, and the biologic basis is unknown. This novel study is designed to address the questions of incidence and biological cause for CICI, while gaining a better understanding of the structural and functional effects of chemotherapy on the brain. In order to address these important objectives, a diverse team of experienced investigators has been assembled to design and implement the proposed protocol. The research team for this project seeks to accomplish the proposed objectives through following mechanisms: 1 assessment of the neurocognitive domains affected in CICI using a tailored battery of cognitive tests to define CICI; 2 measurement of serum markers of oxidative stress and correlation of these markers with neurocognitive test results; and 3 exploration of structural and functional changes in the brain during cognitive tasks and correlation of results with markers of oxidative stress and neurocognitive test results. 